miR-181a是TCRαβ+ CD8+ T大颗粒淋巴细胞白血病STAT3介导生存网络中的新参与者
研究探讨miR-181a在T-LGL白血病STAT3持续激活中的作用,对T-LGL白血病与年龄匹配健康对照TEMRA细胞行miRNA测序发现miR-181a过表达;抑制miR-181a后SOCS3+和DUSP6+ T-LGL细胞增加,转染miR-181a的人CD8+ T细胞基础STAT3和ERK1/2磷酸化增加;在TL1细胞系及另一独立细胞系验证miR-181a通过抑制SOCS3驱动STAT3激活、通过抑制DUSP6促进ERK1/2磷酸化,抑制miR-181a提高FAS介导凋亡敏感性。
要点
- T-LGL白血病与年龄匹配健康对照TEMRA细胞miRNA测序显示miR-181a过表达。
- 抑制miR-181a后SOCS3+和DUSP6+ T-LGL细胞增加,提示其靶向调控STAT3与ERK1/2通路。
- miR-181a通过抑制SOCS3驱动STAT3激活、通过抑制DUSP6促进ERK1/2磷酸化,抑制miR-181a提高FAS介导凋亡敏感性。
核心结论
- miR-181a可能是解释STAT3未突变患者STAT3过度激活的缺失环节。
研究设计与样本
- 对T-LGL白血病病例与年龄匹配健康对照的TEMRA细胞行miRNA测序。
- 使用miR-181a转染的人CD8+ T细胞及人T-LGL细胞系TL1进行机制验证,并在另一独立细胞系中验证该机制。
主要发现
- T-LGL白血病与年龄匹配健康对照TEMRA细胞miRNA测序显示miR-181a过表达。
- 对miR-181a下调靶基因的基因集富集分析(GSEA)提示其参与调控STAT3和ERK1/2通路。
- 流式细胞术分析显示抑制miR-181a后SOCS3+和DUSP6+ T-LGL细胞增加。
- 转染miR-181a的人CD8+ T细胞基础STAT3和ERK1/2磷酸化增加。
- 在TL1细胞中显示miR-181a通过抑制SOCS3驱动STAT3激活、通过抑制DUSP6促进ERK1/2磷酸化,并在独立细胞系中验证;抑制miR-181a导致对FAS介导凋亡的敏感性更高。
关键数值与推荐
- 40%患者STAT3持续激活由STAT3激活突变所致,60%患者原因未知。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
T-LGL cells arise as a consequence of chronic antigenic stimulation and inflammation and thrive because of constitutive activation of the STAT3 and ERK pathway. Notably, in 40% of patients, constitutive STAT3 activation is due to STAT3 activating mutations, whereas in 60% this is unknown. As miRNAs are amongst the most potent regulators in health and disease, we hypothesized that aberrant miRNA expression could contribute to dysregulation of these pathways. miRNA sequencing in T-LGL leukemia cases and aged-matched healthy control TEMRA cells revealed overexpression of miR-181a. Furthermore, geneset enrichment analysis (GSEA) of downregulated targets of miR-181a implicated involvement in regulating STAT3 and ERK1/2 pathways. Flow cytometric analyses showed increased SOCS3+ and DUSP6+ T-LGL cells upon miR-181a inhibition. In addition, miR-181a-transfected human CD8+ T cells showed increased basal STAT3 and ERK1/2 phosphorylation. By using TL1, a human T-LGL cell line, we could show that miR-181a is an actor in T-LGL leukemia, driving STAT3 activation by SOCS3 inhibition and ERK1/2 phosphorylation by DUSP6 inhibition and verified this mechanism in an independent cell line. In addition, miR-181a inhibition resulted in a higher sensitivity to FAS-mediated apoptosis. Collectively, our data show that miR-181a could be the missing link to explain why STAT3-unmutated patients show hyperactive STAT3.
引用
- Assmann JLJC, Leon LG, Stavast CJ, et al. miR-181a is a novel player in the STAT3-mediated survival network of TCRαβ+ CD8+ T large granular lymphocyte leukemia. Leukemia. 2021. PMID: 34873301. doi:10.1038/s41375-021-01480-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。